Veit Bücklein, Dr Med, on CAR-T Outcomes Between Male and Female Patients With LBCL
The postdoctoral researcher at Laboratory for Translational Cancer Immunology, Ludwig-Maximilians-Universität München, discussed the need for research into how CAR T-cells act differently between sexes.
“We think that these findings highlight that there seem to be differences in how CAR T-cells work in male and female patients, and I think we need a better understanding of what these differences are. By understanding these differences, we might be able to address these differences in the future, and thereby improve outcomes of CAR T-cell therapy as a whole, not only for male patients but also for female patients in the future.”
Female patients have significantly superior outcomes then male patients, even after adjusting other known risk variables, following treatment with axicabtagene ciloleucel (axi-cel), Kite Pharma’s chimeric antigen receptor (CAR) T-cell therapy approved for relapsed/refractory large B-cell lymphoma (LBCL) under the name Yescarta. These data were presented by Veit Bücklein, Dr Med, postdoctoral researcher, Laboratory for Translational Cancer Immunology, Ludwig-Maximilians-Universität München, in a poster at the 2023 American Society of Hematology (ASH) Annual Meeting & Exposition, held December 9-12, in San Diego, California.
The data included 119 male and 95 female patients with similar baseline patient characteristics except for ferritin levels (significantly higher in male patients prior to lymphodepletion), similar safety outcomes, but better overall response rate, progression free survival rate, and overall survival in female patients. CGTLive spoke with Bücklein to learn more about the new research and possible reasons for the difference in outcomes. He stressed that further work is needed to dig into how CAR T-cells act different between male and female patients.
Click here to read more coverage of the ASH 2023 meeting.
REFERENCE
Buecklein VL, Rejeski K, Perez A, et al. Impact of sex on clinical outcomes after CD19 CAR T-cell therapy for large B-cell lymphoma: Response and survival are significantly superior in female compared to male patients. Presented at: 2023 ASH Annual Meeting & Exposition, December 9-12; San Diego, California. Abstract 3787.
Evaluating Allogeneic CAR-T P-BCMA-ALLO1 in R/R Multiple Myeloma
November 21st 2024Bhagirathbhai R. Dholaria, MD, an associate professor of medicine in malignant hematology & stem cell transplantation at Vanderbilt University Medical Center, discussed interim data from the phase 1/1b clinical trial evaluating Poseida's CAR-T.
World Pancreatic Cancer Day 2024: Looking Back at Progress in Cell and Gene Therapy
November 21st 2024In observance of World Pancreatic Cancer Day, held on the third Thursday of November each year, we took a look back at the past year's news in cell and gene therapy for pancreatic cancer indications.
